Phase 2 Start
NUVB: Phase 2 Start: A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine i
March 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- March 1, 2027
- Company
- Nuvation Bio Inc. (NUVB)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine i
- Company
- Nuvation Bio Inc. (NUVB)
- Indication
- Glioma; Oligodendroglioma; IDH1-mutant Glioma